What is the AI rating for ACIU?

AC Immune SA (ACIU) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are the risks of investing in ACIU?

Extreme data scarcity prevents fundamental analysis. No revenue, profitability, or cash flow visibility. No balance sheet data to assess financial stability

What is ACIU's revenue growth rate?

AC Immune SA (ACIU) has a revenue growth rate of N/A year-over-year, based on the latest SEC EDGAR filings.

Does ACIU pay dividends?

AC Immune SA (ACIU) does not currently pay dividends.

Where can I find ACIU SEC filings?

Official SEC filings for AC Immune SA (CIK: 0001651625) including 10-K annual reports, 10-Q quarterly reports, and 8-K current reports are available on SEC EDGAR at sec.gov.

What is ACIU's EPS growth?

AC Immune SA earnings per share (EPS) growth is N/A year-over-year. Current diluted EPS is $0.00.

ACIU Stock Analysis - AC Immune SA AI Rating & Fundamentals

Name: AC Immune SA (ACIU) Stock
Brand: AC Immune SA
Rating: 3 (1 reviews)

Investment Thesis

Unable to assess AC Immune SA fundamentals due to insufficient financial data. With only 1 metric available and no income statement, balance sheet, or cash flow information, a meaningful analysis of profitability, financial health, or growth quality cannot be conducted. Data quality is critically inadequate for investment assessment.

ACIU Strengths

-No strengths identified

ACIU Risks

! Extreme data scarcity prevents fundamental analysis
! No revenue, profitability, or cash flow visibility
! No balance sheet data to assess financial stability
! No insider trading activity to gauge management confidence
! Insufficient metrics available (1 out of required 20+) for comprehensive evaluation

Key Metrics to Watch

* Revenue and net income trends when available
* Cash position and burn rate for pre-revenue pharmaceutical development
* Clinical trial progress and pipeline advancement
* Operating cash flow and runway sustainability

ACIU Financial Metrics

Revenue

N/A

Net Income

N/A

EPS (Diluted)

$0.00

Free Cash Flow

N/A

Total Assets

N/A

Cash Position

N/A

ACIU Profitability Ratios

Gross Margin N/A

Operating Margin N/A

Net Margin N/A

ROE N/A

ROA N/A

FCF Margin N/A

ACIU Balance Sheet & Liquidity

Current Ratio

N/A

Quick Ratio

N/A

Debt/Equity

N/A

Debt/Assets

0.0%

Interest Coverage

N/A

Long-term Debt

N/A

ACIU Growth Metrics (YoY)

Revenue Growth

N/A

Year-over-year

Net Income Growth

N/A

Year-over-year

EPS Growth

N/A

Earnings per share

FCF Margin

N/A

Free cash flow / Revenue

ACIU SEC Filings

Access official SEC EDGAR filings for AC Immune SA (CIK: 0001651625)

📄 10-K Annual Reports 📋 10-Q Quarterly Reports 📰 8-K Current Reports 📊 Proxy Statements 🔍 All Filings

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2026-03-19 | Powered by Claude AI